Jon Faiz Kayyem
Jon Faiz Kayyem's purchase track record
How the stock did after each of Jon Faiz Kayyem's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/16/2026 | INBX | $1.00M | pending | pending | — |
| 9/8/2026 | INBX | $568K | pending | pending | — |
| 11/19/2024 | INBX | $1.52M | -8.5% | -8.5% | +0.4% |
| 5/31/2024 | INBX | $5.92M | -10.4% | -6.1% | +14.3% |
| 11/21/2022 | BDSX | $200K | +76.9% | -13.9% | +6.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Biodesix Expands MRD Monitoring Through New Partnerships. Biodesix announced progress in two collaborative programs aimed at tumor‑informed and tumor‑naïve molecular residual disease (MRD) solutions. The company also advanced its MRD monitoring programs by partnering with Bio‑Rad and Thermo Fisher. These developments broaden Biodesix’s portfolio of diagnostic tools for cancer patients.
Transaction History
| INBX | ▲ Buy | Open Market | 5,000 | $500K | 9/23/2026 | View on chart |
| INBX | ▲ Buy | Open Market | 5,000 | $500K | 9/16/2026 | View on chart |
| INBX | ▲ Buy | Open Market | 5,000 | $568K | 9/8/2026 | View on chart |
| INBX | ▼ Sell | Gift | 90,000 | $0 | 3/27/2025 | View on chart |
| INBX | ▼ Sell | Gift | 500,000 | $0 | 12/16/2024 | View on chart |
| INBX | ▼ Sell | Gift | 250,000 | $0 | 12/16/2024 | View on chart |
| INBX | ▼ Sell | Gift | 250,000 | $0 | 12/16/2024 | View on chart |
| INBX | ▼ Sell | Gift | 52,000 | $0 | 12/6/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 18,750 | $266K | 11/20/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 18,750 | $266K | 11/20/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 34,843 | $496K | 11/19/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 34,843 | $496K | 11/19/2024 | View on chart |
| INBX | ▼ Sell | Gift | 89,050 | $0 | 6/24/2024 | View on chart |
| INBX | ▼ Sell | Gift | 10,000 | $0 | 6/24/2024 | View on chart |
| INBX | ▼ Sell | Gift | 10,000 | $0 | 6/24/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 49,284 | $849K | 6/5/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 8,265 | $148K | 6/5/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 65,337 | $1.1M | 6/4/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 23,726 | $433K | 6/4/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 46,792 | $777K | 6/3/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 80,738 | $1.4M | 6/3/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 70,193 | $1.1M | 5/31/2024 | View on chart |
| INBX | ▲ Buy | Grant | 6,250 | — | 5/29/2024 | View on chart |
| INBX | ▲ Buy | Grant | 6,250 | — | 5/29/2024 | View on chart |
| INBX | ▲ Buy | Grant | 806,075 | — | 5/29/2024 | View on chart |
| BDSX | ▲ Buy | Grant | 6,172 | $10K | 8/3/2023 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 145,833 | — | 3/31/2023 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 31,619 | — | 12/21/2022 | View on chart |
| BDSX | ▲ Buy | Open Market | 173,913 | $200K | 11/21/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Inhibrx to Present at Upcoming Scientific Conferences
Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.
Inhibrx to Present at Upcoming Scientific Conferences. Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.